{"id":"placebo-matching-imu-838-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL197194","moleculeType":"Small molecule","molecularWeight":"355.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IMU-838 acts as a selective modulator of intracellular signaling, particularly targeting pathways involved in immune cell activation and differentiation. By modulating these pathways, it reduces the production of pro-inflammatory cytokines and shifts immune responses away from pathogenic Th17 and toward regulatory T cell differentiation, thereby suppressing aberrant immune activation in autoimmune and inflammatory conditions.","oneSentence":"IMU-838 is a selective immunomodulator that inhibits intracellular signaling pathways to reduce pathogenic immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:30.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"},{"name":"Relapsing-remitting multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05134441","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunic AG","startDate":"2021-11-18","conditions":"Multiple Sclerosis","enrollment":1121},{"nctId":"NCT05201638","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunic AG","startDate":"2022-01-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1100},{"nctId":"NCT04379271","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","status":"COMPLETED","sponsor":"Immunic AG","startDate":"2020-06-11","conditions":"COVID-19","enrollment":234},{"nctId":"NCT05054140","phase":"PHASE2","title":"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunic AG","startDate":"2021-09-30","conditions":"Multiple Sclerosis","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo matching vidofludimus calcium"],"phase":"phase_3","status":"active","brandName":"Placebo matching IMU-838 tablets","genericName":"Placebo matching IMU-838 tablets","companyName":"Immunic AG","companyId":"immunic-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IMU-838 is a selective immunomodulator that inhibits intracellular signaling pathways to reduce pathogenic immune responses. Used for Ulcerative colitis, Crohn's disease, Relapsing-remitting multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}